GlassScriptPhysician profile
Vimala Vajjala
NPI 1376902536
$6,007.33
in general payments reported to CMS, 2019-2025
34 companies · $532 in 2025
The $532 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $838 · 2021: $1,396 · 2022: $947 · 2023: $553 · 2024: $918 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,002.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,058.76 | 2021-2024 | Ubrelvy, Botox, Qulipta |
| Ucb, INC. | $833.71 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Allergan, INC. | $665.50 | 2019-2022 | |
| Merz North America, INC. | $523.59 | 2019-2020 | |
| Zoll Respicardia, INC. | $313.03 | 2023-2025 | Remede System |
| Eisai INC. | $268.11 | 2020-2022 | |
| Lundbeck LLC | $234.91 | 2020-2022 | |
| Livanova USA, INC. | $232.01 | 2019-2025 | Vns Therapy |
| Amgen INC. | $198.33 | 2019-2021 | |
| Neurelis, INC. | $177.40 | 2020-2024 | Valtoco |
| Sk Life Science, INC. | $159.30 | 2022-2024 | |
| Merz Pharmaceuticals, LLC | $151.75 | 2021-2022 | |
| Pfizer INC. | $142.44 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $136.17 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $123.48 | 2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $78.61 | 2025 | |
| Inspire Medical Systems, INC. | $76.18 | 2023 | Inspire |
| Harmony Biosciences LLC | $74.72 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $70.72 | 2020-2021 | |
| Horizon Therapeutics Plc | $57.29 | 2021 | |
| Grifols USA, LLC | $56.77 | 2020-2025 | Gamunex-C |
| Mallinckrodt Hospital Products INC. | $47.00 | 2020 | |
| Csl Behring | $44.91 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $41.82 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $41.21 | 2022 | |
| Jazz Pharmaceuticals INC. | $36.72 | 2020-2024 | |
| Neurocrine Biosciences, INC. | $35.89 | 2020 | |
| Adamas Pharmaceuticals, INC. | $24.85 | 2021 | |
| Avanir Pharmaceuticals, INC. | $22.88 | 2019 | |
| Amneal Pharmaceuticals LLC | $21.63 | 2022 | |
| Corcept Therapeutics | $19.41 | 2025 | Korlym |
| Biogen, INC. | $13.19 | 2020 | |
| Promius Pharma LLC | $12.58 | 2019 | |
| Travere Therapeutics, INC. | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vimala Vajjala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.